论文部分内容阅读
1990年9月美国 NCI 批准了 Rosenbeng等应用导入 TNF 基因的肿瘤浸润淋巴细胞(TIL)治疗晚期黑色素瘤病人的研究方案,宣告了恶性肿瘤基因治疗的开始。这一疗法为将具有治疗作用的因子定向导入肿瘤局部有效地杀伤肿瘤提供了有前途的新的途径。基于应用淋巴因子激活的淋巴细胞(LAK)
In September 1990, the United States NCI approved Rosenbeng et al.’s research program for the treatment of patients with advanced melanoma using tumor-infiltrating lymphocytes (TIL) with TNF gene introduction, and announced the beginning of gene therapy for malignant tumors. This therapy provides a promising new approach for the targeted introduction of therapeutic factors into the tumor locally to effectively kill the tumor. Based on lymphokine activated lymphocytes (LAK)